Search
Search filters
Type
Audience
Category
Issue
Last updated
- 20231 results available
- 20222 results available
- 20218 results available
- 20191 results available
- 20181 results available
- 20162 results available
- 20151 results available
- 20141 results available
- 20131 results available
- 20124 results available
- 20092 results available
- 20074 results available
- 20065 results available
- 20057 results available
- 20044 results available
- 20032 results available
- 20025 results available
- 20011 results available
Recall class
Displaying 46 - 52 of 52 items.
Distribution of EVUSHELD (tixagevimab and cilgavimab for injection) with English-Only Vial and Carton Labels
AlertHealth professional risk communication | 2022-04-14
Health Canada puts measures in place for medically necessary products affected by import restriction from 3 facilities in India
AlertInformation update | 2014-10-17
Archived - Health Canada reviewing new safety information on cardiac events in patients taking Losec (omeprazole) or Nexium (esomeprazole)
AlertInformation update | 2007-08-09
Archived – Important Safety Information Regarding Tamoxifen and Incidence of Uterine Malignancies, Stroke and Pulmonary Embolism
AlertHealth professional risk communication | 2002-11-07
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance
AlertHealth professional risk communication | 2022-10-26
EVUSHELD (tixagevimab and cilgavimab for injection) - Risk of Prophylaxis or Treatment Failure due to Antiviral Resistance to specific SARS-CoV-2 Subvariants
AlertHealth professional risk communication | 2023-01-17
Archived – Health Canada advises patients about the risks of CRESTOR® (rosuvastatin)
AlertPublic advisory | 2005-03-03